- China: Low US Interest Rates Threaten Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- White House Plans to Freeze Spending to Cut Deficit
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Today's Market Action
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Israel Going Green
- China's Role as Lender Alters Dynamics for United States
- Inside Wal-Mart's Acai Berry Juice Maker
Text Size 
Wyeth [WYE
Loading...
()
] said quarterly earnings rose a better-than-expected 12% on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.
The trial data shows low doses of Pristiq were effective against both depression and hot flashes and caused less nausea than seen in prior studies of higher doses. Although the new data will take more time for regulators to analyze, it could bolster prospects for its eventual approval and commercial success.
Pristiq is now awaiting U.S. approval as a treatment for both conditions. But Wyeth and investors have been concerned about a high incidence of nausea seen among patients who took the drug in earlier trials to treat depression and hot flashes.
Wyeth expects the FDA to extend its hot-flashes review by three months to examine data from the low-dose trials and expects the agency to decide by the first quarter of 2008 whether to approve Pristiq as a treatment for depression.
The company earned $1.25 billion, or 92 cents a share, compared with $1.12 billion, or 82 cents a share, in the year-ago period.
Excluding special items, Wyeth earned 94 cents a share. Analysts on average expected 87 cents a share, according to Reuters Estimates.
Total revenue in the period increased 11% to $5.4 billion for the 2007 first quarter. Prevnar, Wyeth's vaccine for infections, was the biggest gainer by sales in the quarter,
jumping 43% to $617 million.
Antidepressant Effexor continued to be Wyeth's top seller at $891 million in the period, but sales slid 6% from a year earlier due to increased competition.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
Data is a real-time snapshot *Data is delayed at least 15 minutes